New course of treatment with existing drugs for cervical cancer reduces risk of death by 35%

BioX­cel tout­ed da­ta Thurs­day morn­ing claim­ing that Igal­mi, its drug for ag­i­ta­tion episodes, suc­ceed­ed in a piv­otal tri­al with Alzheimer’s pa­tients, re­duc­ing a com­pos­ite of

There are several challenges to the delivery of novel gene therapies to market, which non-viral gene therapy technology may potentially address, particularly on drug efficacy.